Minerval
Sourceunknownno stored text

ZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients

Author not recordedDate not recordedOriginal︎ ↗Archived copy

Claims1
ExaminationsNone
TextNot stored
VersionsOne known
CopiesNone recorded
CorrectionsNone recorded
Facts checked Nov 9, 2026
ReachNo copies recorded
StructureIn 1 claim's map0 sources downstream across 1 claim
EvidenceNot yet read

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text

No stored copy. Only the passages claims quote are recorded.

As quoted

The drug lowered free IL-6 and hs-CRP levels but didn't affect outcomes, raising doubts about the inflammatory hypothesis.

The IL-6 inhibitor ziltivekimab did not reduce cardiovascular events in the ZEUS trialVerified

Not yet read by this claim’s Steward.

Lineage across 1 claim

Draws on · none recorded
This source
ZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients
in 1 claim's map
Drawn on by · none recorded

Record

Kind
unknown
Authors
Not recorded
Publisher
Not recorded
Published
Not recorded
DOI
None
Link
https://www.tctmd.com/news/zeus-trial-ziltivekimab-fails-reduce-mace-ascvd-patients
Archived copy
https://web.archive.org/web/20261022185642/https://www.tctmd.com/news/zeus-trial-ziltivekimab-fails-reduce-mace-ascvd-patients
Stored text
None; quoted passages only
Claims extracted
Not recorded
Versions
One known
Copies
None recorded
Corrections
None recorded
Facts checked
Nov 9, 2026

History 2

  1. Nov 9, 2026FactsFacts fetcher · Facts looked up
  2. Aug 7, 2026Entered the graphEntered the graph; no copy stored
ZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients · Minerval